• Mashup Score: 0

    While survival has improved during the past decades as a result of advances in treatment, head and neck squamous cell carcinoma is the sixth most common malignancy in the world and accounts for about 4% of all U.S. cancer cases. In 2023, an estimated 66,920 patients will be diagnosed with the disease in the United States. The main environmental risk factor for the disease is tobacco use; however, alcohol consumption and testing positive for the human papillomavirus may also increase the risk of developing

    Tweet Tweets with this article
    • Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma https://t.co/Hx1x32Dpw2 #hncsm #headneckcancer #oncology

  • Mashup Score: 0

    In a phase II trial (RTOG 3501, TRYHARD) reported in JAMA Oncology, Wong et al found that the addition of lapatinib to chemoradiotherapy with cisplatin did not appear to improve progression-free survival in front-line therapy for stage III to IV non–human papillomavirus (HPV)-related head and neck carcinoma. One hundred and twenty-seven patients from sites in the United States and Canada were enrolled into the double-blind trial between October 2012 and April 2017. Patients were r andomly assigned to

    Tweet Tweets with this article
    • Non–HPV-Related Head and Neck Cancer: Adding a TKI to CRT https://t.co/gglWOLCqYE #hncsm #headneckcancer #oncology

  • Mashup Score: 0

    Fewer and higher doses of radiation may be effective at treating patients with head and neck squamous cell carcinoma, according to new findings presented by Bentzen et al at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract LBA 02). Head and neck squamous cell carcinoma—the seventh most common type of cancer in the world—accounts for 450,000 deaths per year and is predominantly diagnosed in patients who reside in low- and middle-income countries. Historically, the disease

    Tweet Tweets with this article
    • Reducing the Burden of Head and Neck Cancer in Low- and Middle-Income Countries https://t.co/2P6hCOAcjb #hncsm #headneckcancer #oncology #radonc #ASTRO23

  • Mashup Score: 0

    While survival has improved during the past decades as a result of advances in treatment, head and neck squamous cell carcinoma is the sixth most common malignancy in the world and accounts for about 4% of all U.S. cancer cases. In 2023, an estimated 66,920 patients will be diagnosed with the disease in the United States. The main environmental risk factor for the disease is tobacco use; however, alcohol consumption and testing positive for the human papillomavirus may also increase the risk of developing

    Tweet Tweets with this article
    • Oral Health in Patients With Head and Neck Cancer https://t.co/Hx1x32CRGu #hncsm #headneckcancer #oncology

  • Mashup Score: 0

    In a Korean phase II trial (KCSG HN 15-16 TRIUMPH) reported in the Journal of Clinical Oncology, Keam et al described results of a personalized biomarker-driven umbrella trial for the treatment of patients with platinum-refractory recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) using matched molecular targeted agents. In the multicenter trial, targeted next-generation sequencing was performed between October 2017 and August 2020 in 203 patients. Patients were assigned to treatment

    Tweet Tweets with this article
    • Personalized Biomarkers for Treatment of HNSCC https://t.co/glNJyjHffb #hncsm #headneckcancer #oncology #biomarkers #genomics

  • Mashup Score: 0

    Head and neck cancers comprise approximately 4% of all new cancer diagnoses globally and represent approximately 110,000 new cancer diagnoses and 17,000 cancer deaths annually in the United States. Head and neck cancers are a heterogenous group of malignancies where prognosis and treatment varies… Pembrolizumab plus chemoradiation therapy failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation therapy alone in patients with locally advanced head and neck

    Tweet Tweets with this article
    • Head and Neck Cancers 2022–2023 Almanac, w/Guest Editors Thomas J. Roberts, MD, MBA, and Lori Wirth, MD https://t.co/S3Gf8w7bX3 #hncsm #headneckcancer #oncology @the_tjroberts @MGHMedicine @MGHCancerCenter

  • Mashup Score: 0

    Researchers have found a way to use artificial intelligence (AI) to diagnose sarcopenia in patients with head and neck cancer. The tool may be used to improve treatment and supportive care for patients, according to a report published by Ye et al in JAMA Network Open. “Sarcopenia is an indicator that the patient is not doing well. A real-time tool that tells us when a patient is losing muscle mass would trigger us to intervene and do something supportive to help,” said lead study author Benjamin Kann,

    Tweet Tweets with this article
    • AI-Driven Muscle Mass Assessment May Aid in Detecting Sarcopenia in Patients With Head and Neck Cancer https://t.co/mnQGzT6eZ3 #hncsm #sarcopenia #headneckcancer #oncology #AI

  • Mashup Score: 0

    In a Taiwanese study reported in the Journal of Clinical Oncology, Lou et al compared two methods of Epstein-Barr Virus (EBV)-screening to identify nasopharyngeal carcinoma. Blood samples were obtained from 819 incident Taiwanese nasopharyngeal carcinoma cases (including 213 cases of early-stage disease) diagnosed between 2010 to 2014, as well as from 1,768 controls matched for age and sex from the same region. EBV assessments consisted of an EBV antibody score using immunoglobulin A antibodies measured

    Tweet Tweets with this article
    • EBV-Based Screening Methods for Identifying Nasopharyngeal Carcinoma https://t.co/oHdEhUXuQz #EBV #screening #hncsm #headneckcancer #oncology